메뉴 건너뛰기




Volumn 17, Issue 5, 2012, Pages 823-831

Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

EID: 84865727463     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2100     Document Type: Article
Times cited : (28)

References (39)
  • 1
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
    • Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
    • (2004) Ann Intern Med , vol.140 , pp. 346-355
    • Hadziyannis, S.J.1    Sette Jr., H.2    Morgan, T.R.3
  • 2
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
    • (2002) N Engl J Med , vol.347 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 3
    • 70349533037 scopus 로고    scopus 로고
    • Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
    • Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
    • (2009) Nat Genet , vol.41 , pp. 1105-1109
    • Tanaka, Y.1    Nishida, N.2    Sugiyama, M.3
  • 4
    • 79952308232 scopus 로고    scopus 로고
    • Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C
    • Villa E, Karampatou A, Cammà C, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011; 140:818-829.
    • (2011) Gastroenterology , vol.140 , pp. 818-829
    • Villa, E.1    Karampatou, A.2    Cammà, C.3
  • 5
    • 78751508078 scopus 로고    scopus 로고
    • Hepatitis C pharmacogenetics: State of the art in 2010
    • Afdhal N, McHutchison J, Zeuzem S, et al. Hepatitis C pharmacogenetics: state of the art in 2010; Hepatology 2011; 53:336-345.
    • (2011) Hepatology , vol.53 , pp. 336-345
    • Afdhal, N.1    McHutchison, J.2    Zeuzem, S.3
  • 6
    • 34247539146 scopus 로고    scopus 로고
    • The impact of insulin resistance, serum adipocytokines and visceral obesity on liver steatosis and fibrosis in patients with chronic hepatitis C
    • Lo Iacono O, Venezia G, Petta S, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on liver steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 25:1181-1191.
    • (2007) Aliment Pharmacol Ther , vol.25 , pp. 1181-1191
    • Lo Iacono, O.1    Venezia, G.2    Petta, S.3
  • 7
    • 69849109303 scopus 로고    scopus 로고
    • Time course of insulin resistance during antiviral therapy in non-diabetic, noncirrhotic patients with genotype 1 HCV infection
    • Petta S, Cammà C, Di Marco V, et al. Time course of insulin resistance during antiviral therapy in non-diabetic, noncirrhotic patients with genotype 1 HCV infection. Antivir Ther 2009; 14:631-639.
    • (2009) Antivir Ther , vol.14 , pp. 631-639
    • Petta, S.1    Cammà, C.2    Di Marco, V.3
  • 8
    • 15744381704 scopus 로고    scopus 로고
    • Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
    • Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128:636-641.
    • (2005) Gastroenterology , vol.128 , pp. 636-641
    • Romero-Gómez, M.1    Del Mar Viloria, M.2    Andrade, R.J.3
  • 9
    • 0041822106 scopus 로고    scopus 로고
    • Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C
    • Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
    • (2003) Hepatology , vol.38 , pp. 645-652
    • Davis, G.L.1    Wong, J.B.2    McHutchison, J.G.3    Manns, M.P.4    Harvey, J.5    Albrecht, J.6
  • 10
    • 23444460553 scopus 로고    scopus 로고
    • Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ ribavirin
    • Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ ribavirin. J Hepatol 2005; 43:425-433.
    • (2005) J Hepatol , vol.43 , pp. 425-433
    • Ferenci, P.1    Fried, M.W.2    Shiffman, M.L.3
  • 11
    • 28844451934 scopus 로고    scopus 로고
    • Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    • Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44:97-103.
    • (2006) J Hepatol , vol.44 , pp. 97-103
    • Zeuzem, S.1    Buti, M.2    Ferenci, P.3
  • 12
    • 48749099989 scopus 로고    scopus 로고
    • Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response
    • Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135:451-458.
    • (2008) Gastroenterology , vol.135 , pp. 451-458
    • Ferenci, P.1    Laferl, H.2    Scherzer, T.M.3
  • 13
    • 46249114151 scopus 로고    scopus 로고
    • Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial
    • Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47:1884-1893.
    • (2008) Hepatology , vol.47 , pp. 1884-1893
    • Yu, M.L.1    Dai, C.Y.2    Huang, J.F.3
  • 14
    • 84984562129 scopus 로고    scopus 로고
    • Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial
    • Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47:1260-1269.
    • (2008) Clin Infect Dis , vol.47 , pp. 1260-1269
    • Liu, C.H.1    Liu, C.J.2    Lin, C.L.3
  • 15
    • 38649090347 scopus 로고    scopus 로고
    • Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
    • Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47:43-50.
    • (2008) Hepatology , vol.47 , pp. 43-50
    • Mangia, A.1    Minerva, N.2    Bacca, D.3
  • 16
    • 68949183162 scopus 로고    scopus 로고
    • Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients
    • Berg T, Weich V, Teuber G, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009; 50:369-377.
    • (2009) Hepatology , vol.50 , pp. 369-377
    • Berg, T.1    Weich, V.2    Teuber, G.3
  • 17
    • 70349292099 scopus 로고    scopus 로고
    • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    • Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
    • (2009) Nature , vol.461 , pp. 399-401
    • Ge, D.1    Fellay, J.2    Thompson, A.J.3
  • 18
    • 70349548852 scopus 로고    scopus 로고
    • IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
    • Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
    • (2009) Nat Genet , vol.41 , pp. 1100-1104
    • Suppiah, V.1    Moldovan, M.2    Ahlenstiel, G.3
  • 19
    • 70349533037 scopus 로고    scopus 로고
    • Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
    • Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
    • (2009) Nat Genet , vol.41 , pp. 1105-1109
    • Tanaka, Y.1    Nishida, N.2    Sugiyama, M.3
  • 20
    • 77949831342 scopus 로고    scopus 로고
    • Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study
    • Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338-1345.
    • (2010) Gastroenterology , vol.138 , pp. 1338-1345
    • Rauch, A.1    Kutalik, Z.2    Descombes, P.3
  • 21
    • 77953881002 scopus 로고    scopus 로고
    • Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
    • Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:120-129.
    • (2010) Gastroenterology , vol.139 , pp. 120-129
    • Thompson, A.J.1    Muir, A.J.2    Sulkowski, M.S.3
  • 22
    • 33646590308 scopus 로고    scopus 로고
    • Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
    • Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43:954-960.
    • (2006) Hepatology , vol.43 , pp. 954-960
    • Jensen, D.M.1    Morgan, T.R.2    Marcellin, P.3
  • 23
    • 71549129264 scopus 로고    scopus 로고
    • Insulin resistance predicts rapid virological response in non-diabetic, noncirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin
    • Grasso A, Malfatti F, De Leo PD, et al. Insulin resistance predicts rapid virological response in non-diabetic, noncirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009; 51:984-990.
    • (2009) J Hepatol , vol.51 , pp. 984-990
    • Grasso, A.1    Malfatti, F.2    De Leo, P.D.3
  • 24
    • 17144399925 scopus 로고    scopus 로고
    • Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection
    • Schiefke I, Fach A, Wiedmann M, et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005; 11:1843-1847.
    • (2005) World J Gastroenterol , vol.11 , pp. 1843-1847
    • Schiefke, I.1    Fach, A.2    Wiedmann, M.3
  • 25
    • 0034796623 scopus 로고    scopus 로고
    • Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease
    • Duarte MP, Farias ML, Coelho HS, et al. Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol 2001; 16:1022-1027.
    • (2001) J Gastroenterol Hepatol , vol.16 , pp. 1022-1027
    • Duarte, M.P.1    Farias, M.L.2    Coelho, H.S.3
  • 26
    • 0030012271 scopus 로고    scopus 로고
    • Metabolic bone disease of liver cirrhosis: Is it parallel to the clinical severity of cirrhosis?
    • Chen CC, Wang SS, Jeng FS, Lee SD. Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 1996; 11:417-421.
    • (1996) J Gastroenterol Hepatol , vol.11 , pp. 417-421
    • Chen, C.C.1    Wang, S.S.2    Jeng, F.S.3    Lee, S.D.4
  • 27
    • 34147144615 scopus 로고    scopus 로고
    • Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease
    • Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 2007; 5:513-520.
    • (2007) Clin Gastroenterol Hepatol , vol.5 , pp. 513-520
    • Fisher, L.1    Fisher, A.2
  • 28
    • 77950624679 scopus 로고    scopus 로고
    • Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C
    • Petta S, Cammà C, Scazzone C, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51:1158-1167.
    • (2010) Hepatology , vol.51 , pp. 1158-1167
    • Petta, S.1    Cammà, C.2    Scazzone, C.3
  • 29
    • 16544367410 scopus 로고    scopus 로고
    • Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system
    • Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004; 80 Suppl 6:1717S-1720S.
    • (2004) Am J Clin Nutr , vol.80 , Issue.SUPPL. 6
    • Cantorna, M.T.1    Zhu, Y.2    Froicu, M.3    Wittke, A.4
  • 31
    • 84865781704 scopus 로고    scopus 로고
    • The beneficial effect of vitamin D combined with Peg interferon and ribavirin for chronic HCV infection
    • Abu-Mouch S, Fireman Z, Jarchovsky J, Assy N. The beneficial effect of vitamin D combined with Peg interferon and ribavirin for chronic HCV infection. J Hepatol 2010; 52 Suppl 1:55.
    • (2010) J Hepatol , vol.52 , Issue.SUPPL. 1 , pp. 55
    • Abu-Mouch, S.1    Fireman, Z.2    Jarchovsky, J.3    Assy, N.4
  • 32
    • 77953207214 scopus 로고    scopus 로고
    • Review article: Specifically targeted anti-viral therapy for hepatitis C - A new era in therapy
    • Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment Pharmacol Ther 2010; 32:14-28.
    • (2010) Aliment Pharmacol Ther , vol.32 , pp. 14-28
    • Lange, C.M.1    Sarrazin, C.2    Zeuzem, S.3
  • 33
    • 17144469684 scopus 로고    scopus 로고
    • Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. American Diabetes Association: Clinical Practice Recommendations 2000 Committee Report
    • American Diabetes Association
    • American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. American Diabetes Association: Clinical Practice Recommendations 2000 Committee Report. Diabetes Care 2000; 23 Suppl 1:S4-S19.
    • (2000) Diabetes Care , vol.23 , Issue.SUPPL. 1
  • 34
    • 0021813187 scopus 로고
    • Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
    • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
    • (1985) Diabetologia , vol.28 , pp. 412-419
    • Matthews, D.R.1    Hosker, J.P.2    Rudenski, A.S.3    Naylor, B.A.4    Treacher, D.F.5    Turner, R.C.6
  • 35
    • 0042671303 scopus 로고    scopus 로고
    • Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease
    • Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39:239-244.
    • (2003) J Hepatol , vol.39 , pp. 239-244
    • Colloredo, G.1    Guido, M.2    Sonzogni, A.3    Leandro, G.4
  • 36
    • 0026072529 scopus 로고
    • Classification of chronic viral hepatitis: A need for reassessment
    • Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374.
    • (1991) J Hepatol , vol.13 , pp. 372-374
    • Scheuer, P.J.1
  • 37
    • 0033406371 scopus 로고    scopus 로고
    • EASL International Consensus Conference on Hepatitis C, Paris, 26-27 February 1999 Consensus Statement
    • EASL International Consensus Conference on Hepatitis C, Paris, 26-27 February 1999 Consensus Statement. J Hepatol 1999 Suppl 1; 31:S3-S8.
    • (1999) J Hepatol , vol.31 , Issue.SUPPL. 1
  • 38
    • 0003514370 scopus 로고
    • SAS/STAT software: Changes and enhancement
    • release 6.07. Cary, NC: SAS Institute, Inc.
    • SAS Technical Report, SAS/STAT software: changes and enhancement, release 6.07. Cary, NC: SAS Institute, Inc. 1992.
    • (1992) SAS Technical Report
  • 39
    • 61849096685 scopus 로고    scopus 로고
    • Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future
    • Cammà C, Petta S. Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: looking to the future. J Hepatol 2009; 50:648-651.
    • (2009) J Hepatol , vol.50 , pp. 648-651
    • Cammà, C.1    Petta, S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.